Quantcast

Latest Proton pump inhibitors Stories

2010-11-25 21:43:30

Despite the reassurances of Pasternak and Hviid in their study, "Use of Proton-Pump Inhibitors (PPI) in Early Pregnancy and the Risk of Birth Defects," featured in the Nov. 24 issue of the New England Journal of Medicine, an epidemiologist from Boston University School of Medicine (BUSM) believes that further studies are needed. The original study found that on the basis of data from more than 840,000 live births in Denmark, there was no evidence to suggest that the use of the most common...

2010-10-26 07:00:00

CINCINNATI, Oct. 26 /PRNewswire/ -- Celebrating the return of the NFL season, Prilosec OTC® - the #1 pharmacist recommended over-the-counter heartburn medicine according to Pharmacy Times - has teamed up with two of the NFL's toughest offensive lineman to showcase the importance of powerful protection when it comes to treating frequent heartburn. New York Giants All-Pro Offensive Tackle David Diehl and Minnesota Vikings Guard Anthony Herrera have teamed up with Prilosec...

2010-10-18 16:00:33

Baclofen, esomeprazole investigated as treatments The impact of upper GI conditions, like gastroesophageal reflux disease (GERD) and functional dyspepsia, on sleep"”and treatments aimed at providing relief to heartburn/acid reflux patients who suffer from disordered sleep"”were explored in three new studies related to sleep dysfunction presented today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas. Functional dyspepsia is a...

2010-09-22 11:29:00

DEXILANT is the First Proton Pump Inhibitor (PPI) with a DUAL DELAYED RELEASE (DDR) Technology MISSISSAUGA, ON, Sept. 22 /PRNewswire/ - To view this Social Media Release, please enter the following address in your web browser. http://smr.newswire.ca/en/takeda-canada-inc/patients-living-with-gerd-now-have-a-new-treatment SOURCE Takeda Canada Inc.

2010-08-02 15:32:04

The risk factors for CDAD recurrence have been described as advanced age, severe underlying disease such as renal impairment, multiple episodes of previous CDAD infection, and high white blood cell counts. Recent literature suggests that the use of gastric acid suppressive agents, especially proton pump inhibitors (PPIs) is associated with CDAD recurrence, although results appear to be conflicting. A research article to be published on July 28, 2010 in the World Journal of Gastroenterology...

2010-07-27 07:00:00

PARIS, July 27 /PRNewswire-FirstCall/ -- Medco Research Institute(TM), LLC, a wholly owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor (PPI), a commonly prescribed category of heartburn medications. The study will examine the impact that the PPI, Prevacid® (lansoprazole), has on the effect of two different anti-platelet agents,...

2010-07-01 07:00:00

WOODCLIFF LAKE, N.J., July 1 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 20mg/1100mg and 40mg/1100mg strengths of omeprazole and sodium bicarbonate capsules to the trade. Omeprazole and sodium bicarbonate capsules are the generic version of Santarus' Zegerid®. Annual U.S. sales of Zegerid capsules are approximately $195 million, according to IMS Health data. Par has been awarded 180 days of marketing...

2010-07-01 06:25:00

CINCINNATI, July 1 /PRNewswire/ -- Prasco Laboratories announced today that it is now shipping the authorized generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules. Authorized generics are generic pharmaceuticals manufactured identically to the brand product and sold under a private label. Under the terms of a distribution and supply agreement with Santarus, Prasco will sell and distribute the capsule form of Omeprazole/Sodium Bicarbonate in 20 mg and 40 mg...

2010-05-25 14:53:00

Labeling changes will include new safety information SILVER SPRING, Md., May 25 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors. The product labeling will be changed to describe this possible increased risk. (Logo:...

2010-05-05 08:00:00

NEW ORLEANS, May 5 /PRNewswire/ -- What: Data results from a recent retrospective analysis of DEXILANT delayed release capsules and lansoprazole were presented at Digestive Disease Week (DDW) 2010 in New Orleans. DEXILANT is a proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation. Takeda recently announced that the product trade name for dexlansoprazole in the United States would be changed to DEXILANT from KAPIDEX(TM) (dexlansoprazole). The medical community...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related